Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
prostate cancer
Biotech
Arcus, Gilead drop A2R inhibitor in prostate cancer
Arcus Biosciences and Gilead have decided not to advance their A2R inhibitor in prostate cancer after taking a look at some early clinical data.
James Waldron
Aug 7, 2023 11:00am
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Aug 3, 2023 8:09am
Teleflex flexes with $650M deal for urology spacer maker Palette
Jul 26, 2023 10:34am
Arvinas advances anti-resistance cancer drug on sign of efficacy
Jun 8, 2023 9:30am
Convergent circles up $90M for cancer radiopharmaceuticals
May 3, 2023 8:00am
Immunic punts psoriasis and prostate programs to narrow focus
Apr 5, 2023 9:05am
